Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Conjugate Vaccine Market?

The size of the conjugate vaccine market has experienced significant expansion in the past few years. It is projected to increase from $18.9 billion in 2024 to $21.26 billion in 2025, with a compound annual growth rate (CAGR) of 12.5%. The growth in this period can be ascribed to various factors such as disease load, government-supported immunization initiatives, heightened awareness, focus on pediatric vaccination, as well as trends in preventive healthcare.

Expectations are high for a swift expansion in the conjugate vaccine market size in coming years, with projections reaching $33.99 billion in 2029. This growth, presenting a compound annual growth rate (CAGR) of 12.4%, is anticipated due to factors such as wider immunization policies, the changing dynamics of an aging population, the introduction of new vaccine indications, worldwide health security concerns, international cooperation, and economic development effects. For the forecast period, key trends comprise alliances for vaccine distribution, customized strategies for high-risk groups, application in the evolving field of infectious diseases, advancements in the technology for manufacturing vaccines and worldwide health initiatives promoting vaccine equality.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

Which Factor Is Shaping The Future Of The Conjugate Vaccine Market?

The rise in the demand for conjugate vaccines among adults is anticipated to bolster the conjugate vaccine market’s growth. Conjugate vaccines aim to generate a potent immune response against bacterial capsular polysaccharides, thus improving the body’s ability to combat bacterial infections. The administration of conjugate vaccines in adults helps to decrease the chances of serious disease, complications, and spread of these bacterial illnesses by eliciting a strong immune response. For example, in June 2024, the UK Health Security Agency (UKHSA), a public health organization based in the UK, reportedly stated that the ‘6-in-1’ vaccine coverage in the UK remained consistent at 91.7% over a 12-month period. The initial dose of the pneumococcal conjugate vaccine (PCV) stayed at 93.7%. The rotavirus coverage witnessed a growth of 0.6%, attaining 89.3%, while the second dose of the meningitis B vaccine (MenB2) increased by 0.1% to 91.5%. As such, the escalating demand for conjugate vaccines among adults is contributing to the expansion of the conjugate vaccine market.

What Is The Segment-Wise Breakdown Of The Conjugate Vaccine Market?

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

Which Trends Are Redefining The Future Landscape Of The Conjugate Vaccine Industry?

The emergence of innovation in conjugate vaccines is a noteworthy trend that’s gaining traction in the conjugate vaccine market. Businesses functioning in this market are concentrating on the creation of novel conjugate vaccines to maintain their market standing. For instance, Pfizer Inc., a biotechnology and pharmaceutical company from the United States, introduced Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada during June 2022. The purpose of this vaccine is to prevent pneumonia and severe pneumococcal infections in adults who are 18 years old or more. In addition to the 13 serotypes initially covered by Prevnar 13, Prevnar 20 also includes conjugates for an extra seven serotypes, which are linked to severe pneumococcal disease, antibiotic resistance, high fatality rates, and meningitis.

Which Companies Hold The Largest Market Share In The Conjugate Vaccine Sector?

Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

How Does Regional Performance Compare Across The Conjugate Vaccine Industry?

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model